This activity includes a Powered By Patients interview.
Program Description
Pharmacists play a pivotal role in addressing clinical inertia among people living with type 2 diabetes (T2D) who require insulin to reach glycemic goals. Despite advances in insulin formulations and delivery devices, many patients experience challenges with insulin initiation, titration, or persistence due to barriers such as fear of hypoglycemia, injection discomfort, perceived complexity, and emotional distress. More than half of individuals starting insulin report feelings of failure, shame, or anxiety that can interfere with self-management. Understanding patients’ emotions enables pharmacists to build trust, reduce stigma or guilt, and promote open communication around challenges and fears. Taking patients’ perspectives seriously increases engagement in therapy decisions, fosters motivation, and improves adherence, supporting improved treatment engagement and overall well-being.
This panel discussion draws on real patient experiences to help pharmacists translate clinical data into personalized care strategies. Experts will guide learners through practical approaches to identify adherence barriers, optimize insulin therapy, and foster confidence and long-term engagement while prioritizing the individual patient. The discussion will also highlight emerging long-acting insulin formulations that may help alleviate injection burden and support improved persistence in appropriate patients. Upon completion, attendees will receive access to a Train the Trainer toolkit to share knowledge within their clinical practices.
Target audience: Community pharmacists, health system pharmacists, and ambulatory care pharmacists
Type of activity: Application
Release date: July 21, 2026
Expiration date: July 21, 2027
Learner level: Advanced, Intermediate
Time to complete activity: 1.5 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Use patient insights and experiences to express the full context of adherence barriers affecting people with T2D on insulin therapy
- Determine appropriate therapeutic adjustments by reconciling clinical data with patient-reported barriers to achieve individualized glycemic goals
- Customize communication and counseling strategies to individual patient needs and preferences to foster patient self-management and support long-term adherence to insulin regimens
Jennifer Trujillo, PharmD, BCPS, BC-ADM, CDCES, FCCP
Associate Dean for Education and Professor
Skaggs School of Pharmacy and Pharmaceutical Sciences
Department of Clinical Pharmacy
University of Colorado
Aurora, CO
Sneha Baxi Srivastava, PharmD, BCACP, CDCES, DipACLM, FADCES
Associate Director of Skills Education, Associate Professor
Clinical Pharmacist
Rosalind Franklin University College of Pharmacy
Lake County Health Department
North Chicago, IL
Katelyn O’Brien, PharmD, BCPS, CDCES, BC-ADM
Clinical Pharmacist
Boston Medical Center
Boston, MA
Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP
Professor of Pharmacy Practice/Director of Cardiometabolic Services
Massachusetts College of Pharmacy and Health Sciences/Well Life Medical
Boston, MA
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-26-203-H01-P. The activity is available for CE credit through July 21, 2027.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Faculty
Sneha Srivastava, PharmD, BCACP, CDCES, DipACLM, FADCES, has the following relevant financial relationship with an ineligible company to disclose:
Speakers Bureau: Xeris Pharmaceuticals
Katelyn O’Brien, PharmD, BCPS, CDCES, BC-ADM, has the following relevant financial relationships with ineligible companies to disclose:
Consultant (advisory board): Insulet, Lilly
Speakers Bureau: Cequr, Insulet
Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, has the following relevant financial relationships with ineligible companies to disclose:
Speakers Bureau: Abbott Diabetes, Amgen, CeQur, Lilly, Novo Nordisk, Xeris
The following contributors have no relevant financial relationships with ineligible companies to disclose:
Jennifer Trujillo, PharmD, BCPS, BC-ADM, CDCES, FCCP
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Kylie Ferrentino; Brianna Winters; and Chloe Taccetta.
Any relevant financial relationships listed for these individuals have been mitigated.
At least one anonymous peer reviewer was used as part of
content validation and conflict resolution. The peer reviewer has no relevant
financial relationships with ineligible companies to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms